Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's Disease

Phase 3CompletedNCT00203138

Teva Branded Pharmaceutical Products R&D, Inc.306 enrolled

Overview

Patients who completed the study TVP-1012/232 are eligible to enter the extension study to continue their rasagiline therapy for their Parkinson's disease (PD). During this study the patient's safety, tolerability of rasagiline, and effectiveness of this therapy will be monitored.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

306

Conditions

Parkinson's Disease

Interventions

rasagiline mesylateDRUG

Eligibility

Sex: ALLMin age: 35 Years

Medical Language ↔ Plain English

Inclusion Criteria: • Patients who completed evaluations of week 52 of the TVP 1012/232 protocol, where continued rasagiline therapy is warranted, in the opinion of the principal investigator Exclusion Criteria: • Patients having suffered adverse effects that were probably drug-related in the TVP-1012/232 study

Outcomes

Primary Outcomes

Tolerability - Number of patients completing study on their original treatment assignment (dose reduction and dropout)

Time frame: 2.5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.